UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 120

Sortiert nach

Bortezomib (VELCADE®) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits

Annals of oncology, 2006-05, Vol.17 (5), p.813-817

2006

Volltextzugriff (PDF)

Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer

Journal of clinical oncology, 2004-06, Vol.22 (12), p.2284-2293

2004

Volltextzugriff (PDF)

Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer

Annals of oncology, 2015-07, Vol.26 (7), p.1346-1352

2015

Volltextzugriff (PDF)

Imatinib mesylate (Gleevec®) in advanced breast cancer-expressing C-Kit or PDGFR-β: clinical activity and biological correlations

Annals of oncology, 2008-10, Vol.19 (10), p.1713-1719

2008

Volltextzugriff (PDF)

Management of Breast Cancer During Pregnancy Using a Standardized Protocol

Journal of clinical oncology, 1999-03, Vol.17 (3), p.855-861

1999

Volltextzugriff (PDF)

Long-Term Results of Combined-Modality Therapy for Locally Advanced Breast Cancer With Ipsilateral Supraclavicular Metastases: The University of Texas M.D. Anderson Cancer Center Experience

Journal of clinical oncology, 2001-02, Vol.19 (3), p.628-633

2001

Volltextzugriff (PDF)

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer

Journal of clinical oncology, 1998-10, Vol.16 (10), p.3362-3368

1998

Volltextzugriff (PDF)

Prospective Evaluation of Paclitaxel Versus Combination Chemotherapy With Fluorouracil, Doxorubicin, and Cyclophosphamide as Neoadjuvant Therapy in Patients With Operable Breast Cancer

Journal of clinical oncology, 1999-11, Vol.17 (11), p.3412-3417

1999

Volltextzugriff (PDF)

Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations

Clinical & experimental metastasis, 2013-06, Vol.30 (5), p.631-642

2013

Volltextzugriff (PDF)

1871 Inhibition of mTOR in combination with chemotherapy and angiogenic blockade shows activity in metaplastic breast cancer, an aggressive, chemo-refractory subtype of triple-negative breast cancer (TNBC)

European journal of cancer (1990), 2015-09, Vol.51, p.S289-S290

2015

Volltextzugriff (PDF)

Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma

JNCI : Journal of the National Cancer Institute, 2000-02, Vol.92 (3), p.225-233

2000

Volltextzugriff (PDF)

Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer

Journal of clinical oncology, 1996-10, Vol.14 (10), p.2713-2721

1996

Volltextzugriff (PDF)

Anthracycline antibiotics in cancer therapy : focus on drug resistance

Drugs (New York, N.Y.), 1994-02, Vol.47 (2), p.223-258

1994

Volltextzugriff (PDF)

Phase I Study of a Third-Generation Selective Estrogen Receptor Modulator, LY353381.HCl, in Metastatic Breast Cancer

Journal of clinical oncology, 2001-04, Vol.19 (7), p.2002-2009

2001

Volltextzugriff (PDF)

Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect

Annals of oncology, 2002-02, Vol.13 (2), p.218-221

2002

Volltextzugriff (PDF)

Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer

Journal of clinical oncology, 2002-04, Vol.20 (7), p.1800-1808

2002

Volltextzugriff (PDF)

Phase I Study of Stealth Liposomal Doxorubicin in Combination With Gemcitabine in the Treatment of Patients With Metastatic Breast Cancer

Journal of clinical oncology, 2001-03, Vol.19 (6), p.1716-1722

2001

Volltextzugriff (PDF)

Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma

Cancer, 2005-08, Vol.104 (4), p.682-691

2005

Volltextzugriff (PDF)

Comparison of HER‐2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma

Cancer, 2005-05, Vol.103 (9), p.1763-1769

2005

Volltextzugriff (PDF)

Gene Expression Profiles Obtained from Fine-Needle Aspirations of Breast Cancer Reliably Identify Routine Prognostic Markers and Reveal Large-Scale Molecular Differences between Estrogen-negative and Estrogen-positive Tumors

Clinical cancer research, 2003-07, Vol.9 (7), p.2406-2415

2003

Volltextzugriff (PDF)

A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation

Annals of oncology, 2016-10, Vol.27, p.vi46-vi46

2016

Volltextzugriff (PDF)

Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results

Annals of oncology, 1999-04, Vol.10 (4), p.403-411

1999

Volltextzugriff (PDF)

Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks

Journal of clinical oncology, 2005-09, Vol.23 (25), p.5983-5992

2005

Volltextzugriff (PDF)

Treatment of locally advanced breast cancer

Seminars in oncology, 1992-06, Vol.19 (3), p.278

1992

Volltextzugriff (PDF)

1 – 25 von 120

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(111)
Mit Volltextzugriff
(110)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(67)
Humans
(65)
Life Sciences & Biomedicine
(63)
Female
(61)
Oncology
(56)
Middle Aged
(55)
Adult
(51)
Biological And Medical Sciences
(51)
Medical Sciences
(51)
Aged
(45)
Breast Neoplasms - Drug Therapy
(42)
Pharmacology. Drug Treatments
(40)
Antineoplastic Agents
(37)
Chemotherapy
(35)
Breast Neoplasms - Pathology
(31)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(23)
Doxorubicin - Administration & Dosage
(18)
Male
(16)
Treatment Outcome
(16)
Neoplasm Metastasis
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Bortezomib (VELCADE®) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits

Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer

Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer

Imatinib mesylate (Gleevec®) in advanced breast cancer-expressing C-Kit or PDGFR-β: clinical activity and biological correlations

Management of Breast Cancer During Pregnancy Using a Standardized Protocol

Long-Term Results of Combined-Modality Therapy for Locally Advanced Breast Cancer With Ipsilateral Supraclavicular Metastases: The University of Texas M.D. Anderson Cancer Center Experience

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer

Prospective Evaluation of Paclitaxel Versus Combination Chemotherapy With Fluorouracil, Doxorubicin, and Cyclophosphamide as Neoadjuvant Therapy in Patients With Operable Breast Cancer

Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations

1871 Inhibition of mTOR in combination with chemotherapy and angiogenic blockade shows activity in metaplastic breast cancer, an aggressive, chemo-refractory subtype of triple-negative breast cancer (TNBC)

Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma

Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer

Anthracycline antibiotics in cancer therapy : focus on drug resistance

Phase I Study of a Third-Generation Selective Estrogen Receptor Modulator, LY353381.HCl, in Metastatic Breast Cancer

Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect

Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer

Phase I Study of Stealth Liposomal Doxorubicin in Combination With Gemcitabine in the Treatment of Patients With Metastatic Breast Cancer

Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma

Comparison of HER‐2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma

Gene Expression Profiles Obtained from Fine-Needle Aspirations of Breast Cancer Reliably Identify Routine Prognostic Markers and Reveal Large-Scale Molecular Differences between Estrogen-negative and Estrogen-positive Tumors

A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results

Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks

Treatment of locally advanced breast cancer

Suchergebnisse filtern